ISPOR’s Top 10 HEOR Trends for 2024-2025

By Staff Writer

January 12, 2024

Introduction:

The International Society for Health Economics and Outcomes Research (ISPOR) recently released its biennial report detailing the top 10 Health Economics and Outcomes Research (HEOR) trends for 2024-2025. This report, the fifth of its kind, offers a compelling glimpse into the future of healthcare. Providing key trends such as Real-World Evidence (RWE), drug pricing, and Artificial Intelligence (AI) taking centre stage.

The Dominance of Real-World Evidence:

RWE has consistently featured in ISPOR’s reports, therefore appearing as the top trend in the three most recent publications. It is increasingly being used to supplement Randomised Controlled Trials (RCTs) in healthcare decision-making, highlighting its growing significance in the industry.

The Recurring Theme of Drug Pricing:

Drug pricing remains a critical concern, featuring as the second trend in the report. However, the introduction of the Inflation Reduction Act (IRA) in the United States, which allows Medicare to negotiate drug prices, could potentially impact global drug development and innovation.

The Rise of Artificial Intelligence:

AI, the third trend, is becoming an integral part of our daily lives and the healthcare sector. From chatbots to machine learning, AI is being utilised in various ways to provide valuable insights in HEOR.

Balancing Innovation and Affordability:

Furthermore, the fourth trend focuses on fostering innovation while ensuring affordable pricing. This balance is vital for the development of new technologies in the healthcare sector.

In conclusion, the ISPOR HEOR trends report presents a comprehensive overview of the top trends shaping the future of healthcare. As pressures on healthcare systems worldwide continue to increase, these trends provide invaluable insights for stakeholders to inform and improve healthcare decisions.

Reference url

Recent Posts

masitinib prostate cancer trial
        

Masitinib Prostate Cancer Trial Gains FDA and EMA Approval for Phase 3 Study

🚀 What’s the next big thing in prostate cancer treatment?

The recent FDA and EMA authorizations for the masitinib prostate cancer trial could revolutionize care for metastatic castrate-resistant prostate cancer (mCRPC). This groundbreaking study employs a biomarker-driven strategy to optimize treatment outcomes for patients like never before!

Dive into the full article to explore the implications of this targeted therapy and how it may change the future of precision medicine in oncology.

#SyenzaNews #Oncology #PrecisionMedicine #HealthTech

BEBT-908 DLBCL treatment
        

BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhibitor in China

🚀 Are we on the brink of a revolution in DLBCL treatment?

The recent conditional approval of **BEBT-908** by China’s National Medical Products Administration is not just a milestone for oncology, but potentially a game-changer for adults battling relapsed or refractory diffuse large B-cell lymphoma. With its dual-target mechanism, this first-in-class therapy offers promising efficacy and a well-thought-out access strategy that could reshape treatment standards.

Dive into the full article to discover how BEBT-908 is setting new benchmarks in both clinical outcomes and healthcare affordability.

#SyenzaNews #oncology #pharmaceuticals #MarketAccess

AI Cost Implications
    

AI Clinician in Pediatric ICU: A Review and HEOR Perspective

🤖 What could AI Clinician support mean for pediatric ICU care?

A new collaboration between Imperial College London and CHOC is developing an AI system to guide treatment decisions in PICUs. This article reviews the initiative and examines its broader health system implications—offering a Health Economics and Outcomes Research (HEOR) perspective on how AI may shape efficiency, equity, and value in critical care.

Read on to explore how clinical innovation intersects with healthcare economics.

#SyenzaNews #AIinHealthcare #HEOR #PediatricCare #HealthInnovation #PICU

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.